← All trials
NCT05541107
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2023
- Primary completion
- Oct 31, 2024
- Completion date
- Jan 31, 2025
- First posted
- Sep 15, 2022
- Last posted
- Sep 15, 2022
- Enrollment
- 270
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Matinas Biopharma, IncLead sponsor
- Makerere UniversityOverall official - principal investigator
- University of MinnesotaCollaborator
- University of MinnesotaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.